Richard B. Lipton, MD

The director of the Montefiore Headache Center provided an overview of the recent advances in migraine medications and how it has translated to improved care. [WATCH TIME: 2 minutes]

The director of the Montefiore Headache Center provided commentary on how analyses presented at AHS 2022 further support the benefits intranasal zavagepant bring to the migraine treatment landscape. [WATCH TIME: 5 minutes]

The director of the Montefiore Headache Center provided insight on an open-label study presented at AHS 2022 that highlighted rimegepant’s (Nurtec ODT; Biohaven) impact both as a preventative and acute medication. [WATCH TIME: 5 minutes]

The director of the Montefiore Headache Center discussed the intuitiveness and advantages the Migraine Clinical Outcome Assessment System, or MiCOAS, grant provides to clinical trials and patients with migraine. [WATCH TIME: 5 minutes]

The director of the Montefiore Headache Center discussed the momentum within the migraine research community as well as some of the more notable presentations from AHS 2021.

The director of the Montefiore Headache Center discussed future aspirations and potential combinations that should be researched to treat patients with migraine.

The director for the Montefiore Headache Center discussed the COURAGE study and how to effectively use a layered treatment approach with ubrogepant and CGRP monoclonal antibodies.

The director of the Montefiore Headache Center detailed the ways the Migraine Buddy app can help simplify conducting migraine clinical trials while expanding the reach of patients.

The director of the Montefiore Headache Center discussed recent advances in treating migraine both acutely and preventively.

The director of the Montefiore Headache Center discussed the research he would like to see into the treatment, including the potential of combination approaches.

The director of the Montefiore Headache Center discussed how rimegepant has certain benefits over monoclonal antibodies, such as a much shorter half-life.

The director of the Montefiore Headache Center discussed the impact of halving headache days for patients with migraine.

The director of the Montefiore Headache Center discussed how rimegepant was observed to produce clinically meaningful improvements in migraine prevention.

The director of the Montefiore Headache Center discussed his hopes that rimegepant will be approved as a preventive treatment of migraine.

The director of the Montefiore Headache Center discussed how his team’s findings can change the way physicians think about treating migraine.

The director of the Montefiore Headache Center discussed the current landscape of migraine treatments.

The director of the Montefiore Headache Center discussed how different treatments work for different patients with migraine.